TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00283283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Description: A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Description: A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Description: A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Description: A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Description: A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Description: A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Description: A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (Aventis Pasteur inactivated influenza vaccine)
Description: A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002
Study: NCT01915901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo (bismuth subsalicylate)
Description: placebo twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate (DMF)
Description: dimethyl fumarate (DMF) twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate (DMF)
Description: dimethyl fumarate (DMF) twice a day (BID)
Study: NCT02142205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00002
Description: IV Infusion
Study: NCT01575730

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermic intraoperative Peritoneal Chemoperfusion
Description: Dose: 460 mg/m², duration: 30 minutes, temperature 37°C

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hyperthermic intraoperative Peritoneal Chemoperfusion
Description: Dose: 460 mg/m², duration: 30 minutes, temperature 41°C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermic intraoperative Peritoneal Chemoperfusion
Description: Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
Study: NCT00479830

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Eight Focus Groups Consisting of 8-10 Members Each

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Eight Focus Groups Consisting of 8-10 Members Each

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Eight Focus Groups Consisting of 8-10 Members Each

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Eight Focus Groups Consisting of 8-10 Members Each
Study: NCT03836573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation iPad Decision Aid Tool
Description: Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation iPad Decision Aid Tool
Description: Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation iPad Decision Aid Tool
Description: Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.
Study: NCT03834389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case- based Learning
Description: critical thinking, self efficacy, focus group interview
Study: NCT00966563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mangafodipir
Description: Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02887820

Intervention type: DEVICE
Group type: OTHER
Intervention: Thromboelastograph
Description: A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
Study: NCT00513162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Starting Dose of 10 mg/kg By Mouth Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 25 - 50 mg/m\^2 By Mouth Daily
Study: NCT02992847

Intervention type: OTHER
Intervention: Unenhanced MRI

Intervention type: OTHER
Intervention: Unenhanced MRI
Study: NCT04127903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Length of Right Main Stem Bronchus
Description: The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Length of Right Main Stem Bronchus
Description: The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
Study: NCT00634842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
Study: NCT04943354

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taking a person's venous blood
Description: Collection of 5 ml of the patient's venous blood, carried out according to standard rules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taking a person's venous blood
Description: Collection of 5 ml of the patient's venous blood, carried out according to standard rules.
Study: NCT02407210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azilsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil
Study: NCT01947712

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dark chocolate with crossover to milk chocolate
Description: 40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: milk chocolate with crossover to dark chocolate
Description: 40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
Study: NCT04646369

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: screening as usual
Description: Participants in this group will receive usual care at their pediatric primary care practice following information, psychoeducation, and referral to a mental health treatment provider

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Wizard 2.0
Description: Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Wizard 2.0 + SOVA
Description: Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment. SOVA is a peer-support website that social workers and doctors moderate on a 24 hour a day basis.
Study: NCT01276769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin
Description: Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.~1 cycle = 21days 2-6cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and epirubicin
Description: Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.~1 cycle = 21days~2-6cycles
Study: NCT03562390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: The patients will receive treatment using intravenous irinotecan hydrochloride until the patient develops disease progression or fulfills a withdrawal criterion.
Study: NCT04351269

Intervention type: DEVICE
Intervention: CanGaroo Envelope
Description: CanGaroo Envelope with Cardiac Implantable Electronic Device (CIED) implantation

Intervention type: DEVICE
Intervention: TYRX Envelope
Description: TYRX Envelope with Cardiac Implantable Electronic Device (CIED) implantation
Study: NCT01603433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapheon™ Closure System
Description: Sapheon™ Closure System for the treatment of incompetent saphenous veins.
Study: NCT02221999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist
Description: Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT03598699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXR-159
Description: AXR-159 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXR-159
Description: AXR-159 Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXR-159
Description: AXR-159 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: AXR-159 Ophthalmic Solution Vehicle
Study: NCT01383811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Aerobic Exercise
Description: Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list
Description: The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
Study: NCT04040049

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FLT190
Description: Gene Therapy product.
Study: NCT03445533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Arm A: 4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 1, 4, 7, and 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod with Ipilimumab
Description: IMO-2125 intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 16, 20, and 24. WITH (Arm B): Ipilimumab administered as 4 doses on Weeks 2, 5, 8, and 11. in combination with tilsotolimod
Study: NCT00174447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
Study: NCT03796078

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillomandibular advancement
Description: Treatment: Mono or Bimaxillary Orthognathic Surgery. The surgery of Reposition of the jaws is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monomaxillary surgery (isolated MaxS)
Description: Monomaxillary surgery (Isolated MaxS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monomandibullary surgery (MandS)
Description: Monomandibullary surgery (Isolated MandS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
Study: NCT03560570

Intervention type: BIOLOGICAL
Intervention: Coagulation assay
Description: Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin

Intervention type: BIOLOGICAL
Intervention: Coagulation assay
Description: Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin

Intervention type: BIOLOGICAL
Intervention: Coagulation assay
Description: Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin

Intervention type: OTHER
Intervention: Clinical data collection
Description: At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)

Intervention type: OTHER
Intervention: Clinical data collection
Description: At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)

Intervention type: OTHER
Intervention: Clinical data collection
Description: At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
Study: NCT02296749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus tablets 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus tablets 2 mg
Study: NCT00226915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel+Carboplatin
Description: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Carboplatin
Description: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
Study: NCT02148510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monobloc
Description: Construction fitted to upper and lower jaw

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bibloc
Description: Biblock construction
Study: NCT03293836

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multilayer Compressive Bandage
Description: Individual receive multilayer compressive bandage once a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multilayer Compressive Bandage
Description: Individual receive multilayer compressive bandage once a week
Study: NCT01192789

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.

Intervention type: OTHER
Group type: OTHER
Intervention: Referral to Health facility
Description: LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
Study: NCT01579643

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)
Description: 1. The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.~2. The host cornea bed will be prepared with an excimer laser.~3. Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Penetrating Keratoplasty (KP)
Description: 1. A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.~2. The donor cornea is then sutured where the patient's cornea was.
Study: NCT04176289

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PPI measurement
Description: The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI\> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
Study: NCT02389322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5μg/ml ESAT6-CFP10
Description: The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10μg/ml ESAT6-CFP10
Description: The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .